PPIA — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL953003	0.76	20/20
SCHEMBL953004	0.76	20/20
SCHEMBL954750	0.74	20/20
SCHEMBL954752	0.74	20/20
SCHEMBL953426	0.72	20/20
SCHEMBL953429	0.72	20/20
SCHEMBL954002	0.69	20/20
SCHEMBL954003	0.69	20/20
SCHEMBL954309	0.69	20/20
SCHEMBL954311	0.69	20/20
SCHEMBL954312	0.69	20/20
SCHEMBL956366	0.66	20/20
SCHEMBL956367	0.66	20/20
SCHEMBL956368	0.66	20/20
SCHEMBL954539	0.77	19/20
SCHEMBL954540	0.77	19/20
SCHEMBL958035	0.76	19/20
SCHEMBL958036	0.76	19/20
SCHEMBL952172	0.76	19/20
SCHEMBL952174	0.76	19/20

Clinical trials — most relevant to PPIA by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
TMFI Enhances Skin Surface and Epidermal PpIX Fluorescence	PHASE4	COMPLETED
A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia	PHASE3	COMPLETED
Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer.	PHASE1/PHASE2	COMPLETED
Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda	PHASE2	UNKNOWN
Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria	PHASE1	COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors	PHASE1	COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors	PHASE1	COMPLETED
Effectiveness of Physiologic Testing in PPI Non-Responders	EARLY_PHASE1	COMPLETED
Identification of Acute Intermittent Porphyria Modifying Genes	nan	RECRUITING
Role of Circulating Pyrophosphate as a Biomarker of Mediacalcinosis in Type 2 Diabetic Patients	nan	RECRUITING
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING
Portable Measurement of Protoporphyrin IX in the Skin	nan	COMPLETED
A Comparison of White-light and Daylight Topical Methyl 5-aminolaevulinic Acid Photodynamic Therapy for Actinic Keratoses	nan	COMPLETED
Biomarkers in the Diagnosis and Prognosis of NAFLD	nan	RECRUITING
Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing	nan	COMPLETED
Peripheral Perfusion Index in Acute Surgical Patients	nan	COMPLETED
Studies in Porphyria I: Characterization of Enzyme Defects	nan	UNKNOWN
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS	nan	RECRUITING
Treatment Response of Maintenance Dose of Proton Pump Inhibitor in Patients With Nonerosive Gatroesophageal Reflux Disease	nan	COMPLETED
Biomarkers in Idiopathic Juvenile Arthritis	nan	UNKNOWN
Sensorimotor Gating in Schizophrenia	nan	COMPLETED
Neuralized1 and RGS14 Genes	nan	COMPLETED
Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact	nan	COMPLETED
Mitoferrin-1 Expression in Erythropoietic Protoporphyria (Porphyria Rare Disease Clinical Research Consortium (RDCRC))	nan	COMPLETED
Prevalence and Intervention of Hypomagnesemia in Users of Proton-pump Inhibitors	nan	COMPLETED
Cerebellar Mutism Syndrome Study	nan	RECRUITING
Pulmonary Hypertension, Hypoxia and Sickle Cell Disease	nan	COMPLETED
Clinical Diagnosis of Acute Porphyria	nan	COMPLETED
Ovarian Reserve and Matrix Metalloproteinases	nan	COMPLETED
Longitudinal Study of the Porphyrias	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a PPIA binder may also engage these)

Protein	Name	Similarity
Q0ZQK3	—	1.000	Q0ZQK3 →
P62941	—	1.000	P62941 →
Q8HXS3	—	1.000	Q8HXS3 →
P62936	—	1.000	P62936 →
P10111	—	1.000	P10111 →
Q6DTV9	—	1.000	Q6DTV9 →
P62935	—	1.000	P62935 →
P14851	—	1.000	P14851 →
P62938	—	1.000	P62938 →
Q0ZQK6	—	1.000	Q0ZQK6 →
Q0ZQK7	—	1.000	Q0ZQK7 →
Q0ZQL2	—	1.000	Q0ZQL2 →
Q0ZQK8	—	1.000	Q0ZQK8 →
Q9TTC6	—	1.000	Q9TTC6 →
P62940	—	1.000	P62940 →
Q0ZQL0	—	1.000	Q0ZQL0 →
Q0ZQL1	—	1.000	Q0ZQL1 →
Q5R8S7	—	1.000	Q5R8S7 →
P17742	—	1.000	P17742 →
P91791	—	0.997	P91791 →
P54985	—	0.997	P54985 →
P52015	—	0.995	P52015 →
Q9UA41	—	0.993	Q9UA41 →
Q38900	—	0.992	Q38900 →
P0C1I8	—	0.992	P0C1I8 →
Q8W171	—	0.992	Q8W171 →
P0C1H7	—	0.992	P0C1H7 →
Q26565	—	0.991	Q26565 →
P35627	—	0.991	P35627 →
Q9SKQ0	—	0.990	Q9SKQ0 →